Cmed Technology announced the launch of Timaeus Guided Trial Builder (GTB), a new product that introduces a new approach to reduce the time and effort required to start up electronic trials.GTB enables study teams to speed up and simplify Study Setup.
A new survey of 55 large pharmaceutical companies, small biotechs, CROs and non-profit organizations indicates the current industry trial build process takes too long.(1) All respondents indicated the trial build process typically takes weeks or months to complete; no organization indicated an average trial build time shorter than two weeks. The next most common complaints were that the build process: requires too much technical knowledge; is too complicated; does not sufficiently comply with standards; and requires too much work to ensure quality control.
"BioPharmaceutical and research companies want eClinical technology to let them manage more trials with greater speed, higher quality and without increasing resources," said Cmed CEO Dr. David Connelly. "The survey data confirms that the traditional industry trial build tools—after years of trying—do not satisfy these needs. Timaeus Guided Trial Builder addresses the goal of the quick, easy and validated electronic trial with a different approach."
Central to GTB is the Maximal Re-use Template (MRT) approach, which encompass all the common factors and best practices across a sponsor's portfolio and places them in one large validated "super page." MRTs enable rapid build of complete trials without any need of technical programming knowledge. They automatically ensure adherence to standards and seamlessly validate the trial during the build process, eliminating the need for manual quality control (QC) and hand-offs between teams. Adding Guided Trial Builder to Timaeus' on-demand deployment capabilities allows study teams to start new trials and perform mid-trial updates without downtime or site interruption.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.